All articles tagged with #novonordisk
Originally Published 4 months ago — by CNBC
Eli Lilly's obesity pill, orforglipron, despite underwhelming trial data compared to Novo Nordisk's oral semaglutide, remains a competitive option due to its potential advantages in manufacturing, cost, and ease of use, with market predictions favoring Lilly's larger global rollout and market share in the future.
Originally Published 2 years ago — by The Hill
The FDA is investigating reports of serious side effects, including hair loss, suicidal thoughts, and airway obstruction, in patients using GLP-1 receptor agonists like Ozempic and Mounjaro, which are diabetes and weight loss drugs. While these drugs are known for their benefits in stimulating insulin secretion and reducing appetite, the potential new risks are not currently listed as side effects. Novo Nordisk, the manufacturer, acknowledges the FDA's review but stands by the safety and efficacy of its products when used as directed.
Originally Published 2 years ago — by Investor's Business Daily
Novo Nordisk's stock saw a significant rise after announcing two new partnerships aimed at enhancing its weight-loss drug portfolio. The company's collaboration with Omega Therapeutics will explore thermogenesis for fat burning, while a deal with Cellarity will focus on developing a treatment for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. These deals, which could total up to $532 million in payments plus royalties, underscore Novo's commitment to expanding its presence in the obesity and metabolic disease market, building on the success of its diabetes and weight-loss drugs like Ozempic and Wegovy.
Originally Published 2 years ago — by Yahoo Finance
Novo Nordisk has entered into a $1.1 billion research and development deal with two US biotech firms, Omega Therapeutics and Cellarity, to enhance its portfolio in obesity drugs and treatments for Metabolic Dysfunction-associated Steatohepatitis (MASH). The partnerships, which are part of a strategic move to maintain a competitive edge in the rapidly growing obesity drug market, have been positively received by the market, with Novo Nordisk's stock seeing an uptick following the announcement.
Originally Published 2 years ago — by STAT
Novo Nordisk is expanding its obesity treatment portfolio by partnering with two Flagship Pioneering startups, Omega Therapeutics and Cellarity, to develop an mRNA-based obesity drug and a new medication for metabolic-associated fatty liver disease (MASH), respectively. These collaborations mark the first initiatives under a partnership agreement between Flagship and Novo Nordisk established in 2022.
Originally Published 2 years ago — by GlobeNewswire
Novo Nordisk has announced research collaborations with Omega Therapeutics and Cellarity to develop new treatments for cardiometabolic diseases, focusing on obesity management and metabolic dysfunction-associated steatohepatitis (MASH). The collaborations, which are the first under the partnership with Flagship Pioneering, will utilize Omega's epigenomic controller and Cellarity's small molecule therapy platforms. The agreements include potential payments of up to $532 million in milestones and royalties. This partnership aims to leverage cutting-edge technology and deep expertise in cardiometabolic disease to create transformative medicines.